Show simple item record

dc.contributor.authorNguyen, Michael C.
dc.contributor.authorLim, Yean L.
dc.contributor.authorWalton, Antony
dc.contributor.authorLefkovits, Jeffrey
dc.contributor.authorAgnelli, Giancarlo
dc.contributor.authorGoodman, Shaun G.
dc.contributor.authorBudaj, Andrzej
dc.contributor.authorGulba, Dietrich C.
dc.contributor.authorAllegrone, Jeanna
dc.contributor.authorBrieger, David
dc.date2022-08-11T08:08:08.000
dc.date.accessioned2022-08-23T15:44:03Z
dc.date.available2022-08-23T15:44:03Z
dc.date.issued2007-06-15
dc.date.submitted2011-09-23
dc.identifier.citationEur Heart J. 2007 Jul;28(14):1717-22. Epub 2007 Jun 11. <a href="http://dx.doi.org/10.1093/eurheartj/ehm186">Link to article on publisher's site</a>
dc.identifier.issn0195-668X (Linking)
dc.identifier.doi10.1093/eurheartj/ehm186
dc.identifier.pmid17562671
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27229
dc.description.abstractAIMS: To identify factors associated with the use of single or dual antiplatelet therapy in patients prescribed warfarin following coronary stenting and to investigate whether single (aspirin or thienopyridine) vs. dual antiplatelet therapy plus warfarin leads to an excess of adverse outcomes. METHODS AND RESULTS: We analysed data from 800 patients with an acute coronary syndrome who underwent coronary stenting (130 patients received a drug-eluting stent) and were discharged on warfarin and either dual (n = 580) or single (n = 220) antiplatelet therapy. The use of single antiplatelet therapy was more common in Europe than in the USA (34 vs. 17%, P < 0.001). There was no difference in major bleeding in hospital or in 6-month mortality or myocardial infarction. In the single antiplatelet group, the use of either aspirin or thienopyridine (clopidogrel or ticlopidine) in combination with warfarin resulted in similar outcomes. CONCLUSION: Use of single vs. dual antiplatelet therapy and warfarin following stenting is common. In this observational study, there was no difference in mortality or myocardial infarction at 6 months; however, larger trials are needed to assert any firm recommendations.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17562671&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1093/eurheartj/ehm186
dc.subjectAcute Coronary Syndrome
dc.subjectAged
dc.subjectAnticoagulants
dc.subjectAspirin
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectHemorrhage
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPlatelet Activation
dc.subjectPlatelet Aggregation
dc.subjectPlatelet Aggregation Inhibitors
dc.subjectRegression Analysis
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.subject*Stents
dc.subjectSurvival Analysis
dc.subjectTreatment Outcome
dc.subjectWarfarin
dc.subjectHealth Services Research
dc.titleCombining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent
dc.typeArticle
dc.source.journaltitleEuropean heart journal
dc.source.volume28
dc.source.issue14
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/cor_grace/48
dc.identifier.contextkey2254968
html.description.abstract<p>AIMS: To identify factors associated with the use of single or dual antiplatelet therapy in patients prescribed warfarin following coronary stenting and to investigate whether single (aspirin or thienopyridine) vs. dual antiplatelet therapy plus warfarin leads to an excess of adverse outcomes.</p> <p>METHODS AND RESULTS: We analysed data from 800 patients with an acute coronary syndrome who underwent coronary stenting (130 patients received a drug-eluting stent) and were discharged on warfarin and either dual (n = 580) or single (n = 220) antiplatelet therapy. The use of single antiplatelet therapy was more common in Europe than in the USA (34 vs. 17%, P < 0.001). There was no difference in major bleeding in hospital or in 6-month mortality or myocardial infarction. In the single antiplatelet group, the use of either aspirin or thienopyridine (clopidogrel or ticlopidine) in combination with warfarin resulted in similar outcomes.</p> <p>CONCLUSION: Use of single vs. dual antiplatelet therapy and warfarin following stenting is common. In this observational study, there was no difference in mortality or myocardial infarction at 6 months; however, larger trials are needed to assert any firm recommendations.</p>
dc.identifier.submissionpathcor_grace/48
dc.contributor.departmentCenter for Outcomes Research
dc.source.pages1717-22


This item appears in the following Collection(s)

Show simple item record